Immunovant

IMVTleader

Immunovant is developing FcRn inhibitors to reduce disease-causing IgG antibodies in autoimmune diseases, with batoclimab in multiple Phase III trials across 6+ indications.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($0M)

Datos estáticos (cargando finanzas en tiempo real…)

No product revenue (clinical stage) (100%)

Composición de segmentos y clientes principales

Detalles del producto

Batoclimab (IMVT-1402)80%

Subcutaneous FcRn inhibitor reducing IgG antibodies — in Phase III for myasthenia gravis, CIDP, thyroid eye disease, and lupus nephritis.

IMVT-1402 (next-gen)20%

Next-generation FcRn inhibitor with enhanced half-life and selectivity vs. batoclimab for broader autoimmune pipeline.

Relaciones en la Cadena de Suministro

Competidores

Johnson & Johnson

Nipocalimab (FcRn inhibitor)

Impacto: significant

argenx

Vyvgart (efgartigimod)

Impacto: significant

Contexto macro y de mercado

헬스케어Noticias del sector

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Próximos catalizadores

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Immunovant impulsado por IA.

Información de la Empresa

Sede Central

New York, New York, USA

Fundación

2018

Empleados

260

Sitio Web

immunovant.com

Estado del sector — 헬스케어

Noticias del sector